HanchorBio Invited to Participate in the 19th QIC CEO Week
Company to Meet with International Institutional Investors in Singapore to Share Corporate Progress and Strategic Priorities
[Taipei, Shanghai, and San Francisco, April 13, 2026] — HanchorBio, a global clinical-stage biotechnology company developing next-generation immunotherapies for oncology and autoimmune diseases, today announced that it has been invited to participate in the 19th QIC CEO Week hosted by Quantum International Corp (QIC). During the event, the Company will engage in a series of one-on-one and group meetings with international institutional investors to discuss its corporate progress, R&D advancement, and business strategy.
Through these meetings, HanchorBio seeks to further strengthen its engagement with the international capital markets and expand potential partnership opportunities.
The 19th QIC CEO Week is jointly organized by QIC, the Biomedical Technology and Device Research Laboratories of ITRI (ITRI BDL), and AAMA Taipei. This meeting will take place from April 14 to April 16, 2026 at The Fullerton Hotel, Singapore. As one of the region’s notable investor engagement platforms, the forum is expected to bring together approximately 200 representatives from international venture capital firms, family offices, strategic investors, Singapore’s major financial institutions, and leading institutional investors. According to the organizers, participating international institutional investors represent aggregate assets under management of more than US$20 trillion. The forum is expected to provide an important platform for deeper dialogue on industry trends and corporate strategy, while also offering participating Taiwanese companies an opportunity to connect with international investors, demonstrate their differentiated technological strengths, and further optimize shareholder structure.
HanchorBio will be represented by Dr. Scott Liu, Founder, Chairman and Chief Executive Officer, and Alan Tseng, Chief Financial Officer. Through these meetings, the Company will continue its dialogue with institutional investors and further its engagement with the international capital markets while exploring potential collaboration opportunities.
HanchorBio will provide updates on its overall business operations, R&D strategy, product portfolio, and future development plans, with the aim of supporting a broader understanding of the Company’s long-term growth strategy and core strengths.
Group Meeting Schedule
April 15, 2026
- 2:00 pm – 3:00 pm UTC+8
April 16, 2026
- 9:00 am – 10:00 am UTC+8
- 10:10 am – 11:10 am UTC+8
Additional one-on-one meetings will also be held during the event.
HanchorBio remains focused on the development of innovative biologic therapeutics and continues to advance its core technology platforms and product pipeline. By participating in this international investor event, the Company seeks to further strengthen its visibility within the global investment community and support its long-term growth and international development efforts.
About HanchorBio
Based in Taipei, Shanghai, and the San Francisco Bay Area, HanchorBio (7827.TPEx) is a global clinical-stage biotechnology company focused on immuno-oncology and immune-mediated diseases. The company is led by an experienced team with a proven track record in biologics discovery and global development, aiming to reshape the landscape of cancer therapies. HanchorBio’s proprietary Fc-based designer biologics (FBDB™) platform enables the design of multi-functional biologics with diverse targeting modalities, designed to activate both innate and adaptive immune pathways and overcome the current challenges of anti-PD1/L1 immunotherapies. The FBDB™ platform has delivered proof-of-concept data in several in vivo tumor animal models. HanchorBio is advancing a portfolio of innovative biologics designed to address significant unmet medical needs through differentiated molecular configurations in R&D and scalable CMC strategies.
漢康生技受邀參加寬量國際主辦第十九屆 CEO Week 投資論壇
將於新加坡與國際投資機構進行系列交流，分享公司營運進展與策略布局
台北、上海、舊金山，2026年4月13日 — 漢康生技為一家致力於開發次世代免疫療法、聚焦腫瘤與自體免疫疾病的全球臨床階段生技公司，今日宣布受邀參加由寬量國際主辦的「19th QIC CEO Week投資論壇」，將於活動期間與多家國際投資機構進行一對一及團體會議，就公司營運概況、研發進程與業務發展方向進行交流。
漢康生技將與多家機構投資人進行系列交流，展現漢康生技持續深化國際資本市場溝通、拓展潛在合作機會的積極布局。
第19屆 QIC CEO Week 投資論壇由寬量國際與工研院生醫與醫材研究所(ITRI BDL) 以及台北搖籃計畫 (AAMA Taipei) 共同合作，實體會議將於4月14至16日於於新加坡舉行。此次論壇為區域重要的投資人交流平台之一，預計匯聚約200位來自國際創投、家族辦公室、策略投資機構、新加坡主要金融機構及頂尖機構投資人之代表，參與論壇之國際機構投資人所管理之資產規模預計合計超過20兆美元。此一交流平台有助於增進資本市場對產業趨勢及企業發展策略的理解，同時也為參與的台灣企業提供與國際投資機構接軌、展現技術差異化優勢並優化股東結構的重要機會。
本次會議將由漢康生技創辦人、董事長兼執行長劉世高博士，以及財務長曾木增代表出席。依漢康生技議程安排，公司將參與多場團體會議，並另安排多場一對一會議，與不同地區及類型的投資機構進行交流。會議期間，漢康生技將說明公司整體營運現況、研發策略、產品布局及未來發展方向，進一步增進國際投資人對公司長期發展藍圖與核心競爭優勢的了解。
19th QIC CEO Week投資論壇
地點：新加坡 The Fullerton Hotel
團體會議時間：
15 Apr 2026
- 2:00 pm – 3:00 pm UTC+8
16 Apr 2026
- 9:00 am – 10:00 am UTC+8
- 10:10 am – 11:10 am UTC+8
其他另安排多場一對一會議。
漢康生技長期專注於創新生物藥研發，持續推進核心技術平台與產品管線發展。透過參與此次國際投資交流活動，公司期待進一步提升國際能見度，並與全球投資社群建立更緊密連結，為未來成長與國際發展奠定基礎。
關於漢康生技
漢康生技（股票代碼：7827.TPEx）是一家全球臨床階段的生物技術公司，專注於腫瘤免疫學及自體免疫疾病領域，研發總部設於台北，並在上海及美國舊金山灣區設有運營辦公室。公司由一支在生物藥發現與全球開發方面擁有豐富成功經驗的資深團隊領導，致力於重塑癌症治療格局。漢康生技專有的Fc基礎設計生物藥平台能夠開發具有多種靶向模式的多功能生物藥，旨在激活先天性與適應性免疫通路，以突破當前抗PD-1/L1免疫療法的局限。該平台已在多個體內腫瘤動物模型中成功獲得概念驗證數據。通過差異化的分子研發策略與可規模化的CMC工藝開發，漢康生技正推進一系列創新生物藥管線，致力於解決尚未被滿足的重大醫療需求。